The Filing Desk

Johnson & Johnson vs Pfizer

Johnson & Johnson JNJ · Pfizer PFE · Pharmaceuticals

Johnson & Johnson reported revenue of $94.2 billion in fiscal 2025, 1.5 times Pfizer's $62.6 billion in fiscal 2025. Johnson & Johnson's revenue grew 6.0% in its latest year, and Pfizer's fell 1.6%. Free cash flow was $19.7 billion at Johnson & Johnson and $9.1 billion at Pfizer. Their fiscal years end in different months (December 28 and December 31), so the periods don't line up exactly.

Side by side

Johnson & JohnsonPfizer
Latest fiscal yearFY2025, Dec 28, 2025FY2025, Dec 31, 2025
Revenue$94.2B$62.6B
Revenue growth6.0%−1.6%
Revenue growth a year, last 5 years2.7%8.5%
Gross margin67.9%74.3%
Operating margin——
Net margin28.5%12.4%
Free cash flow$19.7B$9.1B
Free cash flow margin20.9%14.5%
Return on capital28.6%7.2%
Net debt to EBITDA0.7x3.2x
Dividends and buybacks$18.3B$9.8B
Change in diluted share count0.0%0.2%
Last close$267.14$27.54
P/E at the last close40.5×39.3×
Insider trades, last 12 monthsbought $257,688, sold $154.4 millionbought $3.0 million, sold $134,661
Piotroski F-score4 of 96 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Johnson & JohnsonPfizer
Operating margin
Percent of revenue
Johnson & JohnsonPfizer
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Johnson & JohnsonPfizer

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Johnson & Johnson and Pfizer pages.